REGULATORY

• Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
  April 13, 2016

• MHLW Advisory Panel to Discuss Ono’s Cancer Drug Carfilzomib on April 25
  April 12, 2016

• With Eyes on Pricey Meds, Cost-Shaving Debate Unabated Despite Likely Tax Hike Delay
  April 11, 2016

• Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
  April 8, 2016

• PMDA to Set Up Hokuriku Branch to Train Asian Regulators
  April 8, 2016

• Editor’s Pick: Five Healthcare Policy News Headlines for March
  April 8, 2016

• MHLW Advisory Panel to Discuss Nobelpharma’s Epilepsy Drug on April 20
  April 8, 2016

• NCCHD Aims to Build “Million-Person Database” on Pediatric Patients; Could Lead to Improvements in Pharmacotherapy
  April 6, 2016

• Govt OKs Action Plan on Drug Resistance
  April 6, 2016

• MEXT to Set Up “Shared Facilities” for Drug Discovery, Push Open Innovation
  April 5, 2016

• MOF Panel Hears Expert’s Opinions on Opdivo Prices
  April 5, 2016

• Key Govt Panel Kicks Off Discussions on Economic, Fiscal Policy Blueprint
  April 5, 2016

• Govt Aims to Reduce Use of Antimicrobials by 33% by FY2020 as Part of Efforts to Fight Resistance
  April 5, 2016

• 14-Day Prescription Limit to Be Discussed toward Next Reform: MHLW Official
  April 4, 2016

• Xarelto under Review for Thrombocytopenia Risk
  April 4, 2016

• Clinical Research Bill Won’t Be Enacted in Current Diet Session: LDP Health Panel Chief
  March 30, 2016

• MHLW OKs AZ’s Tagrisso, Novartis’s Zykadia for Lung Cancer
  March 29, 2016

• PMDA to Establish Asian Regulatory Training Center on April 1
  March 29, 2016

• Panel Finalizes “No Efficacy” Decision for Lysozyme, Pronase; MHLW Issues Notifications for Ethical, OTC Products
  March 28, 2016

• Drug Makers, Distributors Won’t Set Interim Targets for Mandatory Barcode Labeling, but Keep Tabs on Progress
  March 25, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 297
• 298
• 299
• 300
• 301
• 302
• 303
• 304
• 305
• …
• Next ›
• 最終 »